• English
    • español
    • português (Brasil)
  • English 
    • English
    • español
    • português (Brasil)
  • Login
View Item 
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • View Item
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Spotlight of Remdesivir in Comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease 2019 (COVID-19) Pandemic

 
Thumbnail
Date
2020-04-01
Author
Vafaei, Somayeh et al.
Metadata
Show full item record
Abstract
2019-nCoV pandemic has influenced on millions of people’s life across the world, which is caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19). Today, no effective treatment exists; however, scientists are endeavoring to find specific antivirals. The efficacy of several drugs such as remdesivir, ribavirin, favipiravir, oseltamivir and umifenovir are currently undergoing clinical studies in order to discover proper treatment of COVID-19. This article tends to summarize these promising antivirals with potential efficacy against this global challenge. A systematic literature review was performed to screen all of the related papers on COVID-19, using the PubMed, Scopus and Web of Science databases published during five years up to March 22, 2020. We tend to determine the safety and efficacy of remdesivir, ribavirin, favipiravir, oseltamivir and umifenovir. Additionally, we searched Clinicatrial.gov to find ongoing trials. Our search identified seven relevant papers and sixteen ongoing clinical trials. It was clear that there are a few promising therapeutic agents on this horizon. Based on limited evidence in the literature, we suggest that remdesivir treatment, among all of our selected antivirals, accompanied by oxygen inhalations, maintaining fluids, electrolyte and intestinal microbiological modulator balances and nutritional support may be helpful in fighting COVID-19. Based on our systematic results, the use of these antiviral drugs need to be confirmed by ongoing and future clinical trials. The prescription of them in COVID-19 patients should adhere to guidelines to reach better outcome.
 
Subscription is needed to have access to the full version of this article.
 
URI
https://dx.doi.org/10.2139/ssrn.3569866
Collections
  • Technical documents and research evidence on COVID-19

Browse

AllCommunities & CollectionsBy Issue DateAuthorsTitlesCategorySubjectsThis CollectionBy Issue DateAuthorsTitlesCategorySubjects

My Account

LoginRegister

Pan American Health Organization
World Health Organization. Regional Office for the Americas
525 Twenty-third Street, N.W., Washington, D.C. 20037, United States of America

Content Disclaimer (Important notes about the material)

Links

  • WHO International Clinical Trial Registry Platform (ICTRP)
  • WHO Coronavirus disease R&D Blueprint
  • WHO Database of Publications on Coronavirus Disease
  • PAHO Coronavirus Disease
  • PAHO/BIREME Windows of Knowledge COVID-19
  • Evidence aid Coronavirus (COVID-19) resources

  • PAHO Digital Library (IRIS PAHO)
  • Virtual Health Library (VHL)
  • Global Index Medicus (GIM)